This guide is continuously monitored and updated by our AI compliance engine. It tracks legislative changes, board rulings, and regulatory updates for Connecticut in real time — so you always have the most current compliance intelligence.
The telehealth compliance information for Connecticut presented on this page is provided for general informational purposes only and should not be construed as legal advice. The telehealth regulatory landscape is evolving rapidly, with state legislatures, medical boards, and federal agencies frequently updating rules, guidance, and enforcement priorities. While TrueEval makes every effort to keep this information current and accurate, we cannot guarantee that all details reflect the very latest regulatory changes at the time of your visit.
We strongly recommend consulting with a qualified healthcare attorney or compliance professional before making business decisions based on this information. For the most current regulatory requirements, refer directly to your state medical board and relevant licensing authorities. Last reviewed: February 2026.
Connecticut presents a moderately complex, yet generally favorable, regulatory landscape for healthcare companies, particularly those leveraging telehealth. The state has actively embraced telehealth expansion, especially post-pandemic, codifying many emergency measures into permanent law. This commitment is evident in its robust telehealth parity laws and clear definitions for telehealth services. Key regulatory bodies include the Connecticut Department of Public Health (DPH), which oversees licensing and professional boards, and the Department of Consumer Protection (DCP) for pharmacy-related matters. The business climate is characterized by a strong emphasis on consumer protection and professional oversight. While Connecticut maintains a Corporate Practice of Medicine (CPOM) doctrine, it is not as aggressively enforced as in some other states, allowing for certain compliant business structures. Recent legislative actions, such as Public Act 21-9 (codifying telehealth payment parity and expanding eligible providers), Public Act 22-81 (further refining telehealth definitions and requirements), and Public Act 23-134 (addressing controlled substance prescribing via telehealth), demonstrate the state's ongoing efforts to adapt its regulatory framework to modern healthcare delivery. Companies expanding into Connecticut should anticipate a rigorous but navigable licensing process and a regulatory environment that values patient access while upholding professional standards. The state's participation in interstate compacts, such as the Nurse Licensure Compact (NLC), also streamlines certain aspects of multi-state practice. Overall, with careful structuring and adherence to professional board regulations, Connecticut offers a viable market for innovative healthcare models.
Connecticut maintains a Corporate Practice of Medicine (CPOM) doctrine, though its enforcement is generally considered moderate compared to stricter states. The legal basis for CPOM in Connecticut is primarily derived from common law principles and statutory provisions that prohibit unlicensed individuals or entities from practicing medicine or employing licensed professionals in a manner that interferes with their independent medical judgment. There is no single overarching statute explicitly codifying CPOM, but rather a collection of statutes governing professional licensure and corporate formation that implicitly uphold the doctrine. For instance, Conn. Gen. Stat. § 20-9 prohibits the practice of medicine without a license, and Conn. Gen. Stat. § 33-182a et seq. governs professional service corporations, implying that only licensed professionals can own and operate entities providing professional services. This means that generally, non-physicians or lay corporations cannot directly employ physicians or other licensed practitioners to provide medical services, nor can they hold an ownership interest in a professional entity that dictates medical decisions. However, non-physicians can own healthcare businesses that do not directly 'practice medicine,' such as management service organizations (MSOs) that provide administrative, billing, and marketing services to professional practices. The key distinction lies in who controls the clinical decision-making and who receives the professional fees. For telehealth companies, medspas, dental practices, and wellness clinics, this means that the professional entity providing the clinical services must be owned and controlled by licensed professionals. Specifically, a physician or group of physicians must own the professional corporation (PC) or professional limited liability company (PLLC) that employs the medical staff and delivers patient care. Non-physicians can own the MSO that contracts with the PC/PLLC to provide non-clinical services. This structure must be carefully implemented to avoid fee-splitting violations (Conn. Gen. Stat. § 20-14e, prohibiting payment for referrals) and ensure that the MSO does not exert undue influence over clinical decisions or share in professional fees. Dental practices are subject to similar restrictions under Conn. Gen. Stat. § 20-123. Medspas, which often involve a blend of cosmetic and medical procedures, must ensure that all medical treatments are performed by, or under the direct supervision of, licensed medical professionals, and the professional component of the business adheres to CPOM. Wellness clinics offering medical services (e.g., IV therapy, hormone therapy) must also comply with these ownership and operational separation requirements. Failure to comply can result in disciplinary action against the licensed professionals, voiding of contracts, and potential civil or criminal penalties for the unlicensed practice of medicine.
Connecticut has a progressive and well-defined framework for telehealth, largely codified through Public Act 21-9 and further refined by Public Act 22-81 and Public Act 23-134. A provider-patient relationship can be established via telehealth, provided it meets the standard of care that would apply to an in-person encounter. There is no explicit 'prior in-person exam' requirement for establishing this relationship for general medical care, though specific prescribing rules (e.g., for controlled substances) may impose additional requirements. Connecticut permits the use of various modalities for telehealth services. 'Telehealth' is defined broadly in Conn. Gen. Stat. § 19a-906 as the delivery of healthcare services through the use of interactive audio, video, or other electronic media or other telecommunications technology, including, but not limited to, synchronous and asynchronous technologies. This includes: Live Two-Way Audio-Visual Communication (Synchronous): This is the preferred and most commonly accepted modality. Audio-Only (Synchronous): Permitted where appropriate and clinically indicated, particularly for mental health services. Public Act 22-81 explicitly allows audio-only telehealth for behavioral health services if the provider determines it is clinically appropriate. Asynchronous (Store-and-Forward): Permitted, but generally requires the transmission of medical information from a patient or primary site to a distant site provider, which is then reviewed at a later time. This is often used for specialties like dermatology or radiology. There are no specific telehealth registration requirements for providers beyond their standard professional licensure with the Connecticut Department of Public Health. However, out-of-state providers must be licensed in Connecticut to provide services to Connecticut residents, unless they qualify under an interstate compact (e.g., NLC, PSYPACT). Informed consent is a critical component of telehealth delivery. Conn. Gen. Stat. § 19a-906(d) mandates that providers obtain informed consent from the patient, or their legal guardian, prior to the delivery of telehealth services. This consent must include an explanation of the telehealth services, the risks and benefits, and the patient's right to withdraw consent. Documentation of this consent is required. There are generally no geographic restrictions within Connecticut for telehealth delivery, meaning a Connecticut-licensed provider can serve patients anywhere within the state. However, providers must be licensed in Connecticut to treat patients located in Connecticut.
Connecticut's prescribing rules for telehealth, particularly concerning controlled substances, have evolved significantly, with Public Act 23-134 being a key recent development. As of 2025-2026, the ability to prescribe controlled substances via telehealth without a prior in-person examination is generally permitted, aligning with federal changes, but with specific safeguards. For Schedule II-V controlled substances, a provider-patient relationship can be established via telehealth for prescribing, provided the practitioner conducts an appropriate medical evaluation that meets the standard of care. This includes ensuring the practitioner has access to the patient's medical records, performs a thorough assessment, and determines that the prescription is medically necessary and appropriate. Public Act 23-134 specifically addresses this, allowing for telehealth prescribing of controlled substances when the practitioner has established a legitimate medical purpose and acted in the usual course of professional practice. DEA requirements are paramount. Federal DEA regulations (21 CFR Part 1304) require practitioners to be registered with the DEA at the location where they administer, dispense, or prescribe controlled substances. For telehealth, the DEA's recent proposed rules (as of early 2024) indicate that a full in-person medical evaluation may be required for initial controlled substance prescriptions for certain high-risk medications, absent a public health emergency, though exceptions for certain low-risk medications or referral pathways exist. Providers must stay updated on the final DEA rules. PDMP checking is mandatory in Connecticut. Conn. Gen. Stat. § 21a-282 requires prescribers to review the Connecticut Prescription Drug Monitoring Program (PDMP) database prior to prescribing any Schedule II, III, IV, or V controlled substance for a patient, and at least every 90 days thereafter for ongoing therapy. This applies equally to telehealth prescribing. There are quantity or refill limitations consistent with general prescribing practices. For Schedule II opioids, initial prescriptions for acute pain are generally limited to a 7-day supply (Conn. Gen. Stat. § 20-14o), with exceptions for chronic pain or other conditions. Refills for Schedule II substances are generally prohibited, requiring a new prescription. Schedule III-V substances have varying refill limitations. Special rules apply to specific drug classes. For GLP-1s (e.g., for weight loss or diabetes), prescribing via telehealth is permissible if clinically appropriate and supported by a comprehensive medical evaluation, including necessary labs and patient monitoring. For testosterone (a Schedule III controlled substance), similar stringent evaluation, lab monitoring, and PDMP checks are required. For stimulants (e.g., methylphenidate, amphetamines, Schedule II), prescribing via telehealth for ADHD or other conditions requires a thorough diagnostic evaluation and ongoing monitoring. The DEA's evolving rules regarding initial stimulant prescriptions via telehealth without a prior in-person visit are particularly relevant here, and practitioners must ensure compliance with both state and federal mandates. Connecticut emphasizes that telehealth prescribing must adhere to the same standards of care as in-person prescribing, including appropriate patient evaluation, diagnosis, treatment planning, and follow-up.
Connecticut's scope of practice for mid-level providers is relatively progressive, granting significant autonomy to Nurse Practitioners (NPs) while maintaining structured collaboration for Physician Assistants (PAs). Nurse Practitioners (NPs) in Connecticut operate under a form of full practice authority, often referred to as 'independent practice' after a period of collaborative practice. Conn. Gen. Stat. § 20-87a(b) allows Advanced Practice Registered Nurses (APRNs) to practice independently after completing at least three years of practice in collaboration with a physician. After this collaborative period, APRNs can practice without a written collaborative agreement, including diagnosing, prescribing (including controlled substances), and managing patient care within their specialty. They are required to maintain professional liability insurance. Physician Assistants (PAs) in Connecticut operate under a 'supervision' model, though the term 'supervision' has evolved to imply a more collaborative relationship. Conn. Gen. Stat. § 20-12d outlines the scope of practice for PAs, stating they may perform medical services that are delegated by a supervising physician and are within the PA's education, training, and experience. While a written collaborative agreement is not explicitly required by statute for every PA-physician relationship, the physician remains responsible for the overall care of the patient. The PA's scope is defined by the supervising physician's scope and the PA's competencies. The Connecticut Medical Examining Board and the Connecticut Board of Physician Assistants provide guidance on appropriate supervision levels, which can range from direct to indirect, depending on the complexity of the task and the PA's experience. Delegation rules for Medical Assistants (MAs) in Medspas are crucial. MAs in Connecticut are generally limited to performing administrative and basic clinical tasks under the direct supervision of a physician, APRN, or PA. They cannot perform procedures that require independent clinical judgment, such as injections (e.g., Botox, fillers), laser treatments, or IV insertions. These procedures must be performed by a licensed physician, APRN, PA, or a registered nurse (RN) acting under appropriate medical orders and supervision. Medspas must ensure strict adherence to these delegation rules to avoid the unlicensed practice of medicine or nursing. Supervision requirements vary by profession. For APRNs post-collaboration, supervision is not required. For PAs, the supervising physician must be readily available for consultation, either in person or via telecommunication, and regularly review patient charts. For RNs and MAs, direct or indirect supervision by a physician or APRN is typically required, depending on the task and the setting. The DPH and respective professional boards provide detailed guidelines on supervision levels and delegated tasks.
Navigating business structures in Connecticut requires careful attention to the Corporate Practice of Medicine (CPOM) doctrine and fee-splitting prohibitions. For healthcare companies, particularly those offering medical services, the Professional Corporation (PC) or Professional Limited Liability Company (PLLC) structure is essential. Under Conn. Gen. Stat. § 33-182a et seq., professional services, including medicine, dentistry, and nursing, must be rendered by licensed individuals organized as a professional corporation or PLLC. This means that the entity directly employing licensed medical professionals and delivering patient care must be owned by licensed professionals. PC-MSO structures are frequently utilized to comply with CPOM. In this model, the licensed professionals (e.g., physicians, APRNs) own and operate the PC/PLLC that provides the clinical services. A separate, non-professional entity, typically a Management Services Organization (MSO), owned by non-clinicians or investors, contracts with the PC/PLLC to provide non-clinical administrative, billing, marketing, and technological support services. This structure is needed to allow non-licensed individuals to invest in or manage the non-clinical aspects of a healthcare business without violating CPOM. Fee-splitting rules are strictly enforced in Connecticut. Conn. Gen. Stat. § 20-14e prohibits physicians from paying or receiving compensation for referrals. This means that MSO fees must be structured as fair market value compensation for legitimate, non-clinical services rendered, and not as a percentage of professional fees or revenue generated from patient care. The MSO's compensation should not fluctuate based on the volume or value of patient referrals or services. Management Services Agreement (MSA) requirements are critical for the PC-MSO model. The MSA must clearly delineate the services provided by the MSO, the compensation structure (fixed fee, cost-plus, or per-unit fee for services, all at fair market value), and explicitly state that the PC/PLLC retains complete control over all clinical decisions, hiring/firing of clinical staff, and patient care. The MSA should also address data privacy, intellectual property, and termination clauses. How to structure ownership for compliance: The PC/PLLC providing direct medical services must be owned solely by licensed professionals. The MSO can be owned by non-licensed individuals or entities. This separation ensures that clinical autonomy is maintained within the professional entity, while administrative efficiencies are gained through the MSO. For medspas, dental practices, and IV therapy clinics, the same principles apply: the entity performing the licensed professional services must be professionally owned, while a separate MSO can handle the business operations. Any deviation risks allegations of unlicensed practice of medicine, fee-splitting, or violation of CPOM.
Connecticut's regulatory landscape continues to evolve, reflecting a dynamic approach to healthcare innovation and patient protection. Public Act 23-134, enacted in 2023, is a significant development, primarily addressing the prescribing of controlled substances via telehealth. It aligns state law with federal guidance, allowing for initial controlled substance prescriptions via telehealth under specific conditions, emphasizing the need for a legitimate medical purpose and adherence to the standard of care. This act also clarified aspects of the provider-patient relationship in the context of telehealth, particularly for behavioral health services. Public Act 22-81, effective July 1, 2022, further refined Connecticut's telehealth laws, expanding the definition of telehealth to explicitly include audio-only communication for behavioral health services and clarifying reimbursement parity. It also addressed informed consent requirements and the types of providers eligible to deliver telehealth. While no major new CPOM legislation has been introduced in 2024-2026, the Connecticut Department of Public Health (DPH) and professional boards continue to issue interpretive guidance and engage in enforcement actions that clarify existing CPOM principles, particularly concerning medspas and emerging wellness clinics. Enforcement actions often focus on unlicensed individuals performing medical procedures or lay ownership structures that exert undue influence over clinical decisions. Connecticut has been active in interstate compacts. It is a member of the Nurse Licensure Compact (NLC), allowing RNs and APRNs from other compact states to practice in Connecticut without obtaining a separate CT license, provided they meet compact requirements. The state is also a member of the Psychology Interjurisdictional Compact (PSYPACT), facilitating telehealth and temporary in-person practice for psychologists. There is ongoing discussion regarding potential participation in the Interstate Medical Licensure Compact (IMLC), which would streamline physician licensing, but as of early 2025, Connecticut has not yet joined. Companies should monitor legislative sessions for potential bills related to AI in healthcare, data privacy (beyond HIPAA), and further refinements to telehealth or scope of practice for various professionals.
Entering the Connecticut healthcare market requires a methodical approach to ensure compliance. Here's a practical checklist and guidance: 1. Entity Formation & CPOM Compliance: Establish a Professional Corporation (PC) or Professional LLC (PLLC) for clinical services, owned solely by Connecticut-licensed professionals. Simultaneously, form a separate Management Services Organization (MSO) for administrative support. Ensure a robust Management Services Agreement (MSA) is in place, reflecting fair market value for services and explicitly reserving clinical control to the PC/PLLC. 2. Professional Licensing: All providers (physicians, APRNs, PAs, RNs) must hold active, unrestricted Connecticut licenses. Initiate licensing applications well in advance, as processing times can vary (typically 2-4 months). Verify eligibility for interstate compacts (NLC, PSYPACT) if applicable. 3. Telehealth Protocol Development: Draft and implement comprehensive telehealth policies and procedures. This includes informed consent forms (per Conn. Gen. Stat. § 19a-906(d)), patient intake processes, emergency protocols, and documentation standards. Ensure technology platforms are HIPAA-compliant and secure. 4. Prescribing Compliance: For controlled substances, integrate PDMP checks into workflow (Conn. Gen. Stat. § 21a-282). Develop clear protocols for initial telehealth prescribing of controlled substances, adhering to Public Act 23-134 and anticipating final federal DEA telehealth rules. 5. Scope of Practice Adherence: Clearly define roles and responsibilities for all clinical staff (APRNs, PAs, RNs, MAs) based on their Connecticut scope of practice. Ensure appropriate supervision or collaborative agreements are in place where required. Common Pitfalls to Avoid: * Underestimating CPOM: Do not assume a 'lenient' CPOM means no CPOM. Improper ownership or control structures are a primary enforcement target. * Fee-Splitting: Avoid percentage-based MSO fees tied to professional revenue. Ensure all MSO compensation is at fair market value for legitimate services. * Inadequate Informed Consent: Failing to obtain and document proper informed consent for telehealth services. * Ignoring PDMP: Not checking the PDMP for controlled substance prescribing is a serious violation. * Unlicensed Practice: Allowing unlicensed staff or MAs to perform procedures outside their scope, especially in medspas. Timeline Expectations: Licensing can take 2-4 months. Entity formation and MSA drafting typically 1-2 months. Setting up telehealth platforms and protocols 1-2 months. Overall, plan for 4-6 months from initial planning to operational readiness for full compliance.*
This article outlines the Centers for Medicare & Medicaid Services (CMS) requirements for healthcare providers offering telehealth services, focusing on credentialing and Medicare enrollment. It details the specific regulations and flexibilities that impact providers seeking to bill Medicare for virtual care, emphasizing the importance of compliance for continued participation.
State dental boards are actively defining the scope and standards for teledentistry, impacting how dental professionals can provide remote care. These regulations often address patient-provider relationships, technology requirements, consent, and record-keeping, emphasizing parity with in-person care standards. Compliance is crucial for dental practices expanding into virtual services to avoid regulatory scrutiny.
The provision of IV vitamin therapy and hydration services via telehealth requires strict adherence to state-specific regulations regarding the establishment of a valid practitioner-patient relationship, physical examination requirements, and supervision protocols. Many states mandate an in-person initial examination or specific telehealth modalities to ensure patient safety and appropriate medical oversight for these invasive procedures. Healthcare businesses offering these services must meticulously review and comply with the medical practice acts and board rules of each state where they operate.
Medspas leveraging telehealth for oversight across multiple states face complex and varying medical director requirements. Understanding the specific state laws governing physician supervision, corporate practice of medicine, and telehealth regulations is crucial for compliance and avoiding legal pitfalls.
The FDA has issued multiple warnings and guidance regarding the use of compounded semaglutide and tirzepatide, emphasizing that these compounded versions are not FDA-approved and may pose risks. This regulatory stance significantly impacts telehealth weight loss programs that rely on these medications, highlighting critical compliance considerations for prescribers and pharmacies.
Full physician-led clinical encounters with prescribing authority — real provider-patient relationships, not just clearance visits.
Board-certified medical directors for telehealth platforms, medspas, IV therapy clinics, dental sleep medicine, chiropractic practices, and more.
Structured agreements between physicians and mid-level providers ensuring compliant care delivery.
Navigate Corporate Practice of Medicine laws with state-specific compliance frameworks and legal structures.
Systematic clinical documentation reviews ensuring quality standards and regulatory compliance.
Receive instant notifications when Connecticut changes healthcare regulations.
Subscribe to AlertsGet a customized compliance framework for your healthcare operations in Connecticut — telehealth, medspa, IV therapy, or brick-and-mortar. Our team will guide you through every regulatory requirement.